← Back to patent-cliff list
STX-241
Tier C — Watch / tradeSTX-241
Scorpion Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：EGFR 19del, EGFR C797S
Indications (approved)：Non-small cell lung cancer
Regional status
US
Phase II
2024-09-17
EU
Phase II
2024-09-17
China
Phase II
2024-09-17
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of STX-241?
Approved indications include: Non-small cell lung cancer.
When does the STX-241 patent expire?
No public expiry year is available for STX-241 yet; this page updates once verified.
How do I get a quote for STX-241 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01